-+ 0.00%
-+ 0.00%
-+ 0.00%

Neuphoria Achieves $15M Milestone In Merck Partnership With Launch Of Phase 2 Clinical Trial

Benzinga·02/12/2025 12:14:19
Listen to the news

This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain development and commercial milestones associated with the progress of multiple candidates plus royalties on net sales of any licensed medicines.